Minocycline Development for Acute Ischemic Stroke

Susan C. Fagan, Lydia E. Cronic, David C. Hess

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Minocycline, a tetracycline antibiotic, has shown anti-inflammatory, anti-apoptotic, and neuroprotective effects in many models of cerebral ischemia and neurodegenerative disease. Its high penetration of the blood-brain barrier, good safety profile, and delayed therapeutic window make it an ideal candidate for use in stroke. In animal models, minocycline reduced infarct size and improved neurologic outcome when administered acutely, with similar neuroprotective benefits seen following delayed administration. To date, two early phase clinical trials have shown minocycline to be safe and potentially effective in acute ischemic stroke, alone or in combination with tissue plasminogen activator. A large efficacy clinical trial is now needed to confirm previous studies, allow for subgroup analysis, and pinpoint the potential place for minocycline in acute stroke therapy.

Original languageEnglish (US)
Pages (from-to)202-208
Number of pages7
JournalTranslational Stroke Research
Volume2
Issue number2
DOIs
StatePublished - Jun 1 2011

Fingerprint

Minocycline
Stroke
Clinical Trials
Neuroprotective Agents
Tissue Plasminogen Activator
Tetracycline
Brain Ischemia
Blood-Brain Barrier
Neurodegenerative Diseases
Nervous System
Anti-Inflammatory Agents
Animal Models
Anti-Bacterial Agents
Safety
Therapeutics

Keywords

  • Acute stroke
  • Drug development
  • Minocycline
  • Vascular protection

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine

Cite this

Minocycline Development for Acute Ischemic Stroke. / Fagan, Susan C.; Cronic, Lydia E.; Hess, David C.

In: Translational Stroke Research, Vol. 2, No. 2, 01.06.2011, p. 202-208.

Research output: Contribution to journalArticle

Fagan, Susan C. ; Cronic, Lydia E. ; Hess, David C. / Minocycline Development for Acute Ischemic Stroke. In: Translational Stroke Research. 2011 ; Vol. 2, No. 2. pp. 202-208.
@article{ab6ca0c193ba4dae94b32a2ad1e0fd50,
title = "Minocycline Development for Acute Ischemic Stroke",
abstract = "Minocycline, a tetracycline antibiotic, has shown anti-inflammatory, anti-apoptotic, and neuroprotective effects in many models of cerebral ischemia and neurodegenerative disease. Its high penetration of the blood-brain barrier, good safety profile, and delayed therapeutic window make it an ideal candidate for use in stroke. In animal models, minocycline reduced infarct size and improved neurologic outcome when administered acutely, with similar neuroprotective benefits seen following delayed administration. To date, two early phase clinical trials have shown minocycline to be safe and potentially effective in acute ischemic stroke, alone or in combination with tissue plasminogen activator. A large efficacy clinical trial is now needed to confirm previous studies, allow for subgroup analysis, and pinpoint the potential place for minocycline in acute stroke therapy.",
keywords = "Acute stroke, Drug development, Minocycline, Vascular protection",
author = "Fagan, {Susan C.} and Cronic, {Lydia E.} and Hess, {David C.}",
year = "2011",
month = "6",
day = "1",
doi = "10.1007/s12975-011-0072-6",
language = "English (US)",
volume = "2",
pages = "202--208",
journal = "Translational Stroke Research",
issn = "1868-4483",
publisher = "Springer US",
number = "2",

}

TY - JOUR

T1 - Minocycline Development for Acute Ischemic Stroke

AU - Fagan, Susan C.

AU - Cronic, Lydia E.

AU - Hess, David C.

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Minocycline, a tetracycline antibiotic, has shown anti-inflammatory, anti-apoptotic, and neuroprotective effects in many models of cerebral ischemia and neurodegenerative disease. Its high penetration of the blood-brain barrier, good safety profile, and delayed therapeutic window make it an ideal candidate for use in stroke. In animal models, minocycline reduced infarct size and improved neurologic outcome when administered acutely, with similar neuroprotective benefits seen following delayed administration. To date, two early phase clinical trials have shown minocycline to be safe and potentially effective in acute ischemic stroke, alone or in combination with tissue plasminogen activator. A large efficacy clinical trial is now needed to confirm previous studies, allow for subgroup analysis, and pinpoint the potential place for minocycline in acute stroke therapy.

AB - Minocycline, a tetracycline antibiotic, has shown anti-inflammatory, anti-apoptotic, and neuroprotective effects in many models of cerebral ischemia and neurodegenerative disease. Its high penetration of the blood-brain barrier, good safety profile, and delayed therapeutic window make it an ideal candidate for use in stroke. In animal models, minocycline reduced infarct size and improved neurologic outcome when administered acutely, with similar neuroprotective benefits seen following delayed administration. To date, two early phase clinical trials have shown minocycline to be safe and potentially effective in acute ischemic stroke, alone or in combination with tissue plasminogen activator. A large efficacy clinical trial is now needed to confirm previous studies, allow for subgroup analysis, and pinpoint the potential place for minocycline in acute stroke therapy.

KW - Acute stroke

KW - Drug development

KW - Minocycline

KW - Vascular protection

UR - http://www.scopus.com/inward/record.url?scp=79955729003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955729003&partnerID=8YFLogxK

U2 - 10.1007/s12975-011-0072-6

DO - 10.1007/s12975-011-0072-6

M3 - Article

C2 - 21909339

AN - SCOPUS:79955729003

VL - 2

SP - 202

EP - 208

JO - Translational Stroke Research

JF - Translational Stroke Research

SN - 1868-4483

IS - 2

ER -